Early-Stage Schizophrenia Outcome Study (ESO Study)
The ESO Study examines longitudinal changes in schizophrenia, including neurocognitive, behavioural, and genome-wide sequencing measures in relation to clinical outcomes. From 2016 to 2021, the study recruited approximately 250 first-episode schizophrenia (FES) patients during their hospitalisation in Czech inpatient psychiatric facilities and 180 healthy controls (HC), aged between 18 and 60 years. Participants have been assessed at baseline (i.e., at the time of admission to a psychiatric hospital), after 1 year, and after 4 years.
Study design
Cohort, Cohort - clinical
Number of participants at first data collection
246 (FES patients)
181 (HCs)
Age at first data collection
18 - 60 years (FES patients)
18 - 60 years (HCs)
Participant year of birth
Varied (FES patients)
Varied (HCs)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2016
Primary Institutions
National Institute of Mental Health in Czechia (Národní ústav duševního zdraví, NUDZ)
Profile paper DOI
Funders
Charles University
Ministry of Education, Youth and Sports of the Czech Republic (Ministerstvo školství, mládeže a tělovýchovy České republiky, MEYS)
Ministry of Health of the Czech Republic (Ministerstvo zdravotnictví České republiky)
National Institute of Mental Health in Czechia (Národní ústav duševního zdraví, NUDZ)
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – face-to-face
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- Diffusion Tensor Imaging (DTI)
- Functional magnetic resonance imaging (fMRI)
- None
Engagement
Keywords
